Desprendimiento de retina tras la cirugía de cristalino transparente con lentes intraoculares EDOF y multifocales: una revisión narrativa / Retinal detachment after refractive lens exchange with EDOF and multifocal intraocular lenses: A narrative review

La cirugía de cristalino transparente (RLE) permite corregir las ametropías y la presbicia mediante el reemplazo del cristalino por una lente intraocular (LIO), ya sea monofocal, multifocal (MIOL) o de profundidad de foco extendida (EDOF). El desprendimiento de retina (DR) es uno de los eventos adversos más graves tras la RLE. El objetivo de este estudio fue revisar la evidencia y los resultados clínicos relacionados con el riesgo de DR después de la RLE. Se realizó una búsqueda utilizando PubMed y un procedimiento de bola de nieve para identificar estudios originales y series de casos. Según la bibliografía, los pacientes < 60 años con longitudes axiales > 23 mm tienen el mayor riesgo de DR. Solo nueve artículos reportaron la agudeza visual (AV) tras el DR en RLE, y solo 25% de los ojos mostraron una AV > 20/40. Teniendo en cuenta que la disminución de la AV tras el DR se puede dar con todos los tipos de LIO independientemente de su diseño óptico, la actitud más acertada al realizar una RLE sería una cuidadosa selección del paciente, evitando aquellos ojos con factores de riesgo para DR (AU)

Refractive lens exchange (RLE) allows to correct ametropias and presbyopia by replacing the crystalline lens with a monofocal, extended depth of focus or multifocal intraocular lens (IOL). Retinal detachment (RD) is one of the most serious adverse events after RLE. This study aimed to review the evidence related to the risk of RD after RLE and its clinical outcomes. A search using PubMed and a snowball search approach was conducted to identify articles and case reports. According to the literature, patients <60 years old with axial lengths >23 mm have the higher postoperative risk of RD. Only nine articles reported visual acuity (VA) after RD in RLE, and only 25% of eyes had a VA>20/40. Considering that the decrease in VA might be uniform for all types of IOLs after RD, surgeons should focus on preventing the RD by means of selecting the appropriate patient, rather than choosing on a particular IOL optical design (AU)

Retinal detachment after refractive lens exchange: A narrative review.

Refractive lens exchange (RLE) allows to correct ametropias and presbyopia by replacing the crystalline lens with an extended depth of focus or multifocal intraocular lens (IOL). Retinal detachment (RD) is one of the most serious adverse events after RLE. This study aimed to review the evidence related to the risk of RD after RLE and clinical outcomes. A search using PubMed and a snowball search approach was conducted to identify articles and case reports. According to the literature, the risks of RD should be considered in patients <60 years old with axial lengths >23 mm. Only nine articles reported visual acuity (VA) after RD in RLE, and only 25% of eyes had a VA > 20/40. Considering that the decrease in VA might be uniform for all types of IOLs after RD, surgeons should focus on selecting the patient to prevent RD rather than on a particular IOL optical design based on the potential risk of DR.

Ocular and systemic adverse effects of ophthalmic and non ophthalmic medications.

Information related to adverse drug effects caused by ocular medications and ocular adverse effects of systemically administered drugs has increased over the last several decades. Here we review the medical literature over the last four decades to both quantitatively and qualitatively determine the adverse effects of ocular drugs and ocular toxicity of non-ocular drugs. A systematic bibliographic review of the literature was performed with the following terms: "drug treatment", "drug therapy", "ocular adverse effects", "ocular side effects", "ocular toxicity", "systemic side effects", "systemic adverse effects", "systemic toxicity", "ocular drug" and "ophthalmic drug" using the Boolean operators or, and, not. Searches focused on: (1) Ocular side/adverse effects of ophthalmic drugs; (2) Ocular side/adverse effects of systemic drugs; (3) Systemic side/adverse effects of ophthalmic drugs. PubMed was used to perform searches. Limits included: species, human and field tag, abstract/title, dates from 01/01/1971 to 31/12/2010. A sub-selection of references was made by discarding articles that were irrelevant for the topics listed above. Adverse effects of alpha2-adrenergic agonists, beta-adrenergic antagonists, quinine derivatives and antituberculosis agents appear in the literature throughout the period of the review. Adverse effects of newer drugs such as amiodarone, phosphodiesterase 5 inhibitors, antiepileptics, tamoxifen, and its interactions have been published principally in the last two decades. It is imperative for patient safety that knowledge of the adverse effects of drugs on the eye whether topically or systemically administered, and the possible systemic effects of drugs given as ophthalmic medications be emphasized to clinicians.